MX2016010499A - Sistemas y métodos para identificar subtipos del receptor de progesterona. - Google Patents

Sistemas y métodos para identificar subtipos del receptor de progesterona.

Info

Publication number
MX2016010499A
MX2016010499A MX2016010499A MX2016010499A MX2016010499A MX 2016010499 A MX2016010499 A MX 2016010499A MX 2016010499 A MX2016010499 A MX 2016010499A MX 2016010499 A MX2016010499 A MX 2016010499A MX 2016010499 A MX2016010499 A MX 2016010499A
Authority
MX
Mexico
Prior art keywords
systems
methods
subtipos
progesterone receptor
identifying
Prior art date
Application number
MX2016010499A
Other languages
English (en)
Inventor
Gilles Erard
ZUKIWSKI Alexander
Original Assignee
Arno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arno Therapeutics Inc filed Critical Arno Therapeutics Inc
Publication of MX2016010499A publication Critical patent/MX2016010499A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan sistemas y métodos para identificar tumores positivos a progesterona usando anticuerpos específicos de isotipo de receptor de progesterona.
MX2016010499A 2014-04-08 2015-04-07 Sistemas y métodos para identificar subtipos del receptor de progesterona. MX2016010499A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976872P 2014-04-08 2014-04-08
PCT/US2015/024792 WO2015157343A1 (en) 2014-04-08 2015-04-07 Systems and methods for identifying progesterone receptor subtypes

Publications (1)

Publication Number Publication Date
MX2016010499A true MX2016010499A (es) 2017-05-09

Family

ID=54209558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010499A MX2016010499A (es) 2014-04-08 2015-04-07 Sistemas y métodos para identificar subtipos del receptor de progesterona.

Country Status (10)

Country Link
US (1) US20150285803A1 (es)
EP (1) EP3129786A4 (es)
JP (1) JP2017512981A (es)
KR (1) KR20170023771A (es)
CN (1) CN106170701A (es)
AU (1) AU2015243969A1 (es)
CA (1) CA2939241A1 (es)
MX (1) MX2016010499A (es)
RU (1) RU2016133175A (es)
WO (1) WO2015157343A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CN110372786B (zh) * 2019-06-24 2021-08-24 南昌大学 用于制备mPRα单克隆抗体的免疫原

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR440E (fr) 1900-08-31 1903-01-07 Societe F. Revel Pere Et Fils Perfectionnement aux parapluies, ombrelles et en-cas
PT1282443E (pt) * 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US7105642B2 (en) * 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
CN101057144A (zh) * 2004-09-22 2007-10-17 三路影像公司 用于评价乳腺癌预后的方法和组合物
WO2010141485A1 (en) * 2009-06-01 2010-12-09 Samuel Waxman Cancer Research Foundation Compositions and methods to induce differentiation and growth inhibition in breast cancer
US9618512B2 (en) * 2011-04-15 2017-04-11 J-Pharma Co., Ltd. Biomarker for breast cancer
WO2013052652A1 (en) * 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
BR112014013709A2 (pt) * 2011-12-08 2017-08-22 Fund Sales Métodos, composições farmaceuticas, e kits, para tratar cânceres resitentes às antiprogestinas
US20130338016A1 (en) * 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis

Also Published As

Publication number Publication date
AU2015243969A1 (en) 2016-09-01
CN106170701A (zh) 2016-11-30
RU2016133175A (ru) 2018-05-08
EP3129786A4 (en) 2018-03-14
WO2015157343A1 (en) 2015-10-15
CA2939241A1 (en) 2015-10-15
KR20170023771A (ko) 2017-03-06
RU2016133175A3 (es) 2018-12-14
JP2017512981A (ja) 2017-05-25
US20150285803A1 (en) 2015-10-08
EP3129786A1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
IL280917B (en) Cs1 targeted chimeric antigen receptor-modified t cells
IL304772A (en) Antibodies, uses and methods
IL272274A (en) B7-h4 antibodies and methods of use thereof
SA517381664B1 (ar) أجسام مضادة تستهدف مستقبل مقترن ببروتين وطرق استخدامها g
GEAP202114450A (en) Anti-tigit antibodies
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
GEAP202114453A (en) Anti-lag3 antibodies and antigen-binding fragments
CL2016001871A1 (es) Anticuerpos humanos para pd-1
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
PL3152317T3 (pl) Sposoby zbierania hodowli ssaczych komórek
LT3209685T (lt) Antikūnai su vienu duomenu, nukreipti prieš viduląstelinius antigenus
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
HUE046027T2 (hu) Multispecifikus ellenanyag-konstrukciók
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
ME03642B (me) Humana antitijela za pd-l1
PL3101032T3 (pl) Koniugat przeciwciało anty-HER2-lek
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
PL3180362T3 (pl) Przeciwciała swoiste dla MMP9
MX2016010499A (es) Sistemas y métodos para identificar subtipos del receptor de progesterona.
PL3182003T3 (pl) Urządzenie do procesu endotermicznego z ulepszonym układem palników
CL2016002535A1 (es) Sistemas y métodos de sellado para miembros alargados
CL2016002710A1 (es) Anticuerpos monoclonales específicos para cry1ca y métodos de detección relacionados
BR112017002234A2 (pt) anticorpos anti-pd-l1